Loading…
Safety Monitoring Committee recommendation based on trial data.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced that the Safety Monitoring Committee has recommended dose escalation in the ongoing Phase 1b trial for its lead product candidate, PH-762. The decision follows a review of trial data, indicating a favorable safety profile at the current dose levels.
The Phase 1b trial is evaluating the safety, tolerability, and preliminary efficacy of PH-762 in patients with specific medical conditions. The dose escalation will allow researchers to explore higher dose levels, potentially enhancing the therapeutic effects of the candidate.
As of the latest available data, Phio Pharmaceuticals has a free float of 5,677,000 shares and 11,039,900 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.